uniQure to Participate in Multiple Upcoming Industry Conferences in October
September 30 2020 - 7:05AM
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company
advancing transformative therapies for patients with severe medical
needs, today announced that Matt Kapusta, chief executive officer
at uniQure, Maria Cantor, chief communications officer, and Chiara
Russo, associate director of investor relations and communications,
will participate in the following upcoming conferences in October:
- SVB
Leerink CybeRx Series:
Rare & Genetics, October
1, 2020• Members of uniQure’s management
team will participate in virtual one-on-one investor meetings in
the afternoon on Thursday, October 1, 2020.
- Jefferies Virtual Gene
Therapy/Editing Summit,
October 1 –
2, 2020• A fireside chat
with research analyst Suji Jeong, Ph.D. will take place on
Friday, October 2, 2020 from 9:00 – 9:25 a.m. ET. The live webcast
of the chat can be accessed through the link displayed in the
Investor section of the uniQure website. The webcast replay will be
available for at least 72 hours following the live event.• Members
of uniQure’s management team will participate in virtual one-on-one
investor meetings throughout the morning on Friday, October 2,
2020.
- Chardan Virtual
4th Annual Genetic Medicines
Conference, October 5 – 6, 2020• A
fireside chat with research analyst Gbola Amusa will take
place on Tuesday, October 6, 2020 from 1:00 – 1:25 p.m. ET. The
live webcast of the chat can be accessed through the link displayed
in the Investor section of the uniQure website. The webcast replay
will be available for at least 72 hours following the live event.•
Members of uniQure’s management team will participate in virtual
one-on-one investor meetings throughout the afternoon on Tuesday,
October 6, 2020.
About uniQure
uniQure is delivering on the promise of gene therapy – single
treatments with potentially curative results. We are leveraging our
modular and validated technology platform to rapidly advance a
pipeline of proprietary gene therapies to treat patients with
hemophilia B, Huntington's disease, Fabry disease, spinocerebellar
ataxia Type 3 and other diseases. www.uniQure.com
uniQure
Contacts: |
|
|
|
FOR INVESTORS: |
|
FOR MEDIA: |
|
|
|
Maria E. Cantor |
Chiara Russo |
Tom Malone |
Direct: 339-970-7536 |
Direct: 617-306-9137 |
Direct: 339-970-7558 |
m.cantor@uniQure.com |
c.russo@uniQure.com |
t.malone@uniQure.com |
uniQure NV (NASDAQ:QURE)
Historical Stock Chart
From Mar 2024 to Apr 2024
uniQure NV (NASDAQ:QURE)
Historical Stock Chart
From Apr 2023 to Apr 2024